Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bladder Carcinoma in Situ (CIS)”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Early research (Phase 1)Study completedNCT05085990
What this trial is testing

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 10
Testing effectiveness (Phase 2)Study completedNCT04496219
What this trial is testing

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Urothelial Carcinoma In SituRecurrent Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+3 more
Fred Hutchinson Cancer Center 45
Early research (Phase 1)Looking for participantsNCT06022029
What this trial is testing

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Who this might be right for
Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more
OncoNano Medicine, Inc. 168
Large-scale testing (Phase 3)Study completedNCT01316874
What this trial is testing

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Who this might be right for
Carcinoma in SituBladder Cancer
Endo USA Inc., a Keenova Therapeutics Company 90
Large-scale testing (Phase 3)Looking for participantsNCT06545955
What this trial is testing

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals 250
Testing effectiveness (Phase 2)Study completedNCT01731652
What this trial is testing

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Who this might be right for
Carcinoma in SituNon Muscle Invasive Bladder Cancer
Telormedix SA 12
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Large-scale testing (Phase 3)Looking for participantsNCT07480356
What this trial is testing

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics 284
Testing effectiveness (Phase 2)Study completedNCT00023842
What this trial is testing

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 97
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Not applicableNot Yet RecruitingNCT07231809
What this trial is testing

Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients

Who this might be right for
Non Muscle Invasive Bladder CancerBladder CancerCarcinoma in Situ of Bladder+2 more
AC.TA. S.r.l. 50
Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Early research (Phase 1)Study completedNCT05085977
What this trial is testing

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT05951179
What this trial is testing

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 131
Large-scale testing (Phase 3)Active Not RecruitingNCT05024773
What this trial is testing

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Who this might be right for
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a. 130
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Early research (Phase 1)WithdrawnNCT03552796
What this trial is testing

SEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaBladder Cancer Stage 0Bladder Cancer Stage I
University of Southern California
Early research (Phase 1)Not Yet RecruitingNCT07725796
What this trial is testing

Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. 30
Not applicableLooking for participantsNCT05463796
What this trial is testing

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Who this might be right for
Cancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more
Dana-Farber Cancer Institute 5,000
Large-scale testing (Phase 3)Study completedNCT02449239
What this trial is testing

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Who this might be right for
Bladder Cancer
Sesen Bio, Inc. 133
Next Page